



Pulmatrix Announces Presentations at ATS 2012 International Conference

Six Presentations Encompassing Clinical and Preclinical Data

Lexington, Mass., May 16, 2012 -- [Pulmatrix](#), a biotechnology company developing breakthrough therapies for respiratory diseases, today announced that six posters on its [iCALM™](#) and [iSPERSE™](#) inhaled drug platforms have been selected for presentation at the American Thoracic Society (ATS) 2012 International Conference taking place May 18-23, 2012, in San Francisco, CA.

The results presented in these posters will include both clinical and preclinical data that highlight the potential of iCALM and iSPERSE drug candidates for respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis (CF).

Poster Presentation Including Clinical Data on iCALM:

- Monday, May 21 2012 - Poster Viewing: 10:45AM -12:30PM. Session B34 - INFLAMMATORY MECHANISMS IN ASTHMA in Area K (Hall D, North Building, Lower Level): K35. "Inhaled Cationic Airway Lining Modulator (iCALM) Attenuates Allergen-Induced Eosinophilic Bronchitis" p.A2784.

Additional Poster Presentations on iCALM and iSPERSE:

- Sunday, May 20 2012 - 2:00PM - 4:30PM. Session A101 - PHARMACOLOGICAL TREATMENT OF COPD: OLD AND NEW in Room 131 (North Building, Lower Level): 121."Reduced Neutrophilic Airway Inflammation By Inhalation Of Dry Powder Calcium Salts In A Mouse Model Of Sub-Chronic Tobacco Smoke Exposure" p.A2274.
- Monday, May 21 2012 - Poster Viewing: 10:45AM -12:30PM. Session B33 - ASTHMA THERAPY: NOVEL APPROACHES in Area K (Hall D, North Building, Lower Level): K9."iSPERSE: A Novel Inhaled Dry Powder Delivery Platform For The Delivery Of Large Molecule Drugs To The Lung For Local And Systemic Treatments" p.A2761.
- Monday, May 21 2012 - Poster Viewing: 10:45AM -12:30PM. Session B37 - NEW INSIGHTS INTO ASTHMA AND COPD TREATMENT in Area D (Hall D, North Building, Lower Level): D24."Inhaled Calcium Based Dry Powder Enhances Whole Lung Mucociliary Clearance In Sheep" p.A2862.
- Tuesday, May 22 2012 - Poster Viewing: 10:45AM -12:30PM. Session C52 - COPD PATHOGENESIS: HUMAN STUDIES in Area K (Hall D, North Building, Lower Level): K101."Extracellular Calcium During Bacterial Challenge Augments The Innate

Immune Response Of Monocyte Derived Macrophages” p.A4541.

- Tuesday, May 22 2012 - 8:15AM - 10:45AM. Session C22 - ASTHMA THERAPY in Room 3010-3012 (West Building, Level 3): 801.”Cationic Salt Dry Powders Inhibit Inflammatory Responses In A Rhinovirus-Induced Exacerbation Mouse Model Of Allergic Airway Inflammation” p.A3949.

About Pulmatrix

[Pulmatrix](#), Inc. is a [clinical stage](#) biotechnology company developing two novel pulmonary drug platforms, [iCALM™](#) and [iSPERSE™](#), for the prevention, treatment and control of respiratory diseases. iCALM (inhaled cationic airway lining modulators) are first-of-a-kind inhaled therapies to prevent and treat acute exacerbations and improve lung function in patients with chronic respiratory diseases, such as COPD, asthma, cystic fibrosis, idiopathic pulmonary fibrosis (IPF) and bronchiectasis, while also treating and preventing respiratory infections including influenza, ventilator acquired pneumonia (VAP) and respiratory syncytial virus (RSV). iSPERSE (inhaled small particles easily respirable and emittable) is a proprietary dry powder pulmonary drug delivery platform, comprised of small, dense particles with unique capabilities to support efficient, reproducible lung delivery of a broad spectrum of drug classes from small molecule to macromolecule including double- and triple-combination therapies. Pulmatrix’s lead iCALM clinical candidate, PUR118, is in two on-going Phase 1b studies in patients with COPD. The Company is pursuing both proprietary and partnered applications for iCALM and iSPERSE. For additional information about Pulmatrix, please visit <http://www.pulmatrix.com>.

iCALM™ and iSPERSE™ are trademarks of Pulmatrix, Inc.

###

For more information, please contact:

Kathryn Morris

The Yates Network

kathryn@theyatesnetwork.com

845-635-9828